Arousal, emotion regulation and challenging behaviors: Insights from the Autism Inpatient Collection

  • Autism Research
Speaker Matthew Siegel, M.D.
Tufts University
Date & Time


Location

Gerald D. Fischbach Auditorium
160 5th Avenue
New York, NY 10010 United States

Autism Research

Autism Research lectures bring together scientists and scholars to discuss diverse and important topics related to autism.

Video Thumbnail

By clicking to watch this video, you agree to our privacy policy.

 
On 24 January 2018, Matthew Siegel drew upon a new resource, the Autism Inpatient Collection data set, to offer preliminary insights into the relationships between physiologic arousal, emotion dysregulation and the occurrence of challenging behaviors. Such behaviors may represent an attempt to modulate physiologic arousal in minimally verbal individuals with autism spectrum disorders.

His talk was part of the Simons Foundation Autism Research lecture series.

About the Lecture

Emotional and behavioral dysregulation are the primary characteristics youth with autism present in clinical settings and are highly predictive of caregiver stress. But the mechanisms that underlie these phenomena are not well understood. These challenges are compounded for youth who are minimally verbal or have an intellectual disability.

In this lecture, Matthew Siegel drew upon a new resource, the Autism Inpatient Collection data set, to offer preliminary insights into the relationships between physiologic arousal, emotion dysregulation and the occurrence of challenging behaviors. Such behaviors may represent an attempt to modulate physiologic arousal in minimally verbal individuals with autism spectrum disorders (ASD). Siegel presented pilot data, using machine learning approaches, that identify physiologic arousal as a biomarker of distress in ASD and that illustrate an opportunity to predict the onset of challenging behavior in real time. This work seeks to address the critical, parent-identified issue of uncertainty regarding when a challenging behavior may occur and may open new avenues for intervention.

About the Speaker

Matthew Siegel is an associate professor of psychiatry and pediatrics at Tufts University School of Medicine, the vice president for medical affairs, developmental disorders service at Maine Behavioral Healthcare, and a faculty scientist at the Maine Medical Center Research Institute.  He attended Amherst College, Stanford Medical School and trained at Brown University in child psychiatry, psychiatry, and pediatrics. Siegel is the principal investigator of the Autism Inpatient Collection and is an expert in the inpatient treatment of challenging behaviors in individuals with autism and other developmental disorders.

Past Lectures

How emotions shape our memories

Kelsey C. Martin, M.D., Ph.D.Executive Vice President, Autism and Neuroscience
Leonard Mlodinow, Ph.D.Physicist and Author

Have you ever contemplated the difference between a feeling, a thought and a memory? And how do all these things fit together in making us who we are?

Leonard Mlodinow is a theoretical physicist and best-selling author. In his latest book, “Emotional: How Feelings Shape Our Thinking,” he unpacks the role emotions play in our thinking and mental well-being.

Kelsey Martin, director of the Simons Foundation Autism Research Initiative (SFARI) and the foundation’s neuroscience collaborations, has spent much of her career as a neuroscientist seeking to understand better how experiences change brain connectivity to store long-term memories.

What do we mean by ‘autism risk genes’?

David Ledbetter, Ph.D.
Chief Clinical Officer, Dascena

Joseph Buxbaum, Ph.D.
Director, Seaver Autism Center
Professor, Psychiatry, Neuroscience, Genetics and Genomic Sciences
Vice Chair for Research and Vice Chair for Mentoring, Psychiatry, Icahn School of Medicine at Mount Sinai

Heather Mefford, M.D., Ph.D.
Full Member, St. Jude Children’s Research Hospital

David Ledbetter and Joseph Buxbaum discussed whether there are genes for which mutations confer risk specific to autism or whether these genes are really conferring general risk of disrupted brain development. The discussion was moderated by Heather Mefford.

Small molecules, genes and antisense oligonucleotides: Industry perspectives on treatment development for ASD

Federico Bolognani, M.D., Ph.D.
Vice President, Head of Clinical Science, Axial Therapeutics

Stuart Cobb, Ph.D.
Chief Scientific Officer, Neurogene; Research Fellow, University of Edinburgh

Yael Weiss, M.D., Ph.D.
Vice President, Business Development, Ultragenyx

Randy Carpenter, M.D.
Chief Medical Officer, Rett Syndrome Research Trust; Co-Founder, Allos Pharma

Federico Bolognani, Stuart Cobb, and Yael Weiss joined a panel to discuss new industry developments on the use of small molecules, gene therapy and antisense oligonucleotides as treatment approaches for autism spectrum disorders (ASD). The panel discussion was moderated by Randall Carpenter.

Subscribe to our newsletter and receive SFARI funding announcements and news